Healthcare Industry News: Neuropathic Pain
News Release - August 15, 2012
Astellas Pharma Europe Ltd. Appoints Dr Susan Wood as Senior Director, Market AccessSTAINES, England, August 15, 2012 -- (Healthcare Sales & Marketing Network) --Astellas Pharma Europe Ltd. (APEL), the European subsidiary of Tokyo-based Astellas Pharma Inc., one of the world's top 20 pharmaceutical companies, has appointed Dr Susan Wood as Senior Director, Market Access for Astellas Pharma Europe Ltd (APEL). Formerly Senior Brand Director of APEL's Pain Management franchise, she will now drive the Company's market access activities with the aim of establishing its leadership in an area of ever increasing importance, in the face of current economic challenges. She will report directly to Kay Drake, Vice President Marketing, Astellas Pharma Europe Ltd.
Welcoming Susan Wood to her new role, Ken Jones, President and CEO, Astellas Pharma Europe Ltd, said:
"Astellas has proved time and again in recent years that it remains entirely possible to introduce effective new medicines that deliver value for payers - and that health services across Europe are willing to fund. Sue will be working closely with our Affiliates to drive the market access strategy across the Astellas Europe organisation in our key therapeutic areas, focusing on developing evidence-based models from the early stages of R&D until the mature stages of the product lifecycle."
Over the past three years, Susan Wood led the launch of Qutenza™, an innovative treatment for peripheral Neuropathic Pain. The successful introduction of Qutenza has confirmed the value of integrating market access expertise at an early stage of strategic planning, and has also profiled Dr Wood's abilities as a leader.
Commenting on her appointment, Susan Wood said:
"Astellas Pharma Europe has recently launched its Oncology franchise, we are expecting some 11 products to be in launch or early-growth phase in the next three years. We are growing fast in Anti-Infectives, with the recently launched anti-infective Dificlir™, the first new treatment in 50 years for clostridium difficile (C.diff), and we continue to affirm our category leadership in Transplantation and Urology. I am very much looking forward to the challenge of supporting the company to achieve its strategic objectives."
Susan Wood joined Astellas Pharma Europe Ltd in 2008 and has over 13 years' experience in international pharmaceutical marketing, with a particular focus on launch strategies. She previously held roles with Hoffmann-La Roche in Basel, Biogen in Paris and Sanofi Pasteur in Lyon. Before entering the pharmaceutical industry, she worked in clinical research. Her academic background lies in neuroscience, with studies at both Oxford University and Harvard Medical School, and she has a PhD in Biochemistry, specialising in general anaesthesia. Before entering the pharmaceutical industry she was also assistant editor of an international neuroscience journal.
Notes to Editors
About Astellas Pharma Europe Ltd.:
Astellas Pharma Europe Ltd., located in the UK, is the European Headquarters of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation is committed to becoming a global company by combining outstanding research and development (R&D) and marketing capabilities and continuing to grow in the world pharmaceutical market. Astellas Pharma Europe Ltd. coordinates 21 affiliate offices located across Europe, the Middle East and Africa. In addition, the Company has an R&D site and three manufacturing plants in Europe. The company employs approximately 4,200 staff across these regions. For more information about Astellas Pharma Europe, please visit http://www.astellas.eu
Source: Astellas Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.